araag2/HINT huggingface dataset:
Clinical trial NCT01499446 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: gw685698x (fluticasone furoate) 100mcg morning, gw685698x (fluticasone furoate) 100mcg evening, gw685698x (fluticasone furoate) 250mcg evening, placebo
SMILES: [H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Outpatients aged between 16- 65 years.

          -  Male and female; female subjects must be non-child bearing potential or of
             childbearing potenetial with negative pregnancy test and willing to use acceptable
             contraceptive methods

          -  Documented clinical history of persistent asthma first diagnosed at least 6 months
             prior to Visit 1

          -  Currently receiving inhaled short-acting beta-2 agonists for symptom relief

          -  A lung function of between 50 to 90% predicted (PEF)

          -  Increase in PEF of at least15%, 20 minutes after inhalation of 400mcg salbutamol

        Exclusion Criteria:

          -  History of respiratory tract infection and/or exacerbation of asthma within a period
             of 4 weeks prior to Visit 1

          -  History of life-threatening asthma, defined as an asthma episode that required
             intubation and/or was associated with hypercapnoea, respiratory arrest or hypoxia
             seizures.

          -  A history of two or more asthma exacerbations requiring treatment with oral
             corticosteroids or hospitalisation in the 6 months before Visit 1.

          -  Past or present disease that, as judged by the investigator, may affect the outcome of
             this study. These diseases include, but are not limited to, cardiovascular disease,
             malignancy, hepatic disease, renal disease, haematologic disease, neurological
             disease, endocrine disease or pulmonary disease (including, but not confined to,
             chronic bronchitis, emphysema, bronchiectasis with the need of treatment, cystic
             fibrosis and bronchopulmonary dysplasia).

          -  Known or suspected sensitivity to corticosteroids, VENTOLIN, or the constituents of
             ROTADISKS (e.g., lactose).

          -  Undergoing allergen desensitisation therapy.

          -  Neurological or psychiatric disease or history of drug or alcohol abuse that would
             interfere with the subject's proper completion of the protocol requirements.

          -  Is a current smoker or has a smoking history of 10 pack years or more (e.g., 20
             cigarettes/day for 10 years). Note: Current smoker is defined as currently smoking or
             stopped smoking within 6 months of screening visit.
Clinical trial NCT00587275 (phase 2, status: terminated)
Conditions: gastroesophageal reflux disease (gerd)
ICD codes: K22.6, K21.9, K21.00, K21.01
Drugs: ast-120, celphere cp-305
SMILES: [C]
Reason stopped: 
    terminated for lack of enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Body weight 40 to 136 kg (88 to 300 lbs)

          -  Recent history of GERD related symptoms (at least twice weekly) confirmed during
             screening.

          -  Recent history of 8 week PPI treatment without significant improvement

          -  Abnormal bilirubin level as assessed by Bilitec

          -  Normal esophageal pH value (pH<4.0 for <4.2% of the time calculated over a 24 hour
             period)

          -  Platelet count (thrombocytes) >100,000/µL

          -  Normal Hgb and Hct levels

          -  Able and willing to comply with all protocol procedures for the planned duration of
             the study

          -  Able and willing to understand, sign and date an informed consent document, and
             authorize access to protected health information.

          -  Females must be postmenopausal, surgically incapable of bearing children, or
             practicing a reliable method of birth control (hormonal contraceptives, intrauterine
             devices, spermicide and barrier). Partner/spouse sterility may also qualify at the
             Investigator's discretion. Females of child-bearing potential must have a negative
             urine pregnancy test at baseline.

        Exclusion Criteria:

          -  Concurrent GI or other pathology which could interfere with the course of the study
             (e.g., erosive esophagitis, malabsorption, cirrhosis, ascites, bleeding ulcer,
             diabetes, scleroderma, non-GI myopathy or neuropathy etc.) Note: patients with
             Barrett's esophagus (short segment defined as < 3 cm) can be included.

          -  Patients with cancer or undergoing chemotherapy for the treatment of cancer

          -  Patients with a history of upper GI surgery

          -  Patients with GERD complications such as stricture of the esophagus

          -  Contraindication to continued PPI treatment

          -  Patients requiring the concomitant use of NSAIDs for the duration of the study

          -  Uncontrolled systemic disease

          -  Diagnosis of a psychiatric disorder within the past 2 years and not on a stable dose
             of medications for at least 6 months

          -  Other major physical or psychiatric illness in previous 6 months as determined by the
             treating physician

          -  Known hypersensitivity or contraindication to any component of the test product (study
             drug) or diagnostics used

          -  Participation in another study within eight (8) weeks prior to randomization

          -  Unable to attend all visits required by the protocol

          -  Pregnant, breast feeding, or planning to become pregnant during the study
Clinical trial NCT00043862 (phase 2, status: completed)
Conditions: lung cancer, small cell, small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: topotecan
SMILES: CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have newly diagnosed, limited stage SCLC (small cell lung cancer), with
             no prior radiotherapy. Patients are allowed to have had a resection or biopsy.

          -  Women of reproductive potential must have a negative serum pregnancy test at the study
             screening visit.

          -  Patients must give written informed consent to participate in the study.

          -  Patients must be able to take oral medication.

          -  Patients should be completely recovered from recent surgery.

          -  Laboratory criteria: Patients must have adequate bone marrow reserve and adequate
             kidney and liver function.

          -  Patients must be evaluated by the radiation oncologist prior to study entry.

        Exclusion Criteria:

          -  Extensive Stage SCLC.

          -  Women who are pregnant or lactating.

          -  Use of an investigational drug within 30 days prior to the first dose of study
             medication.

          -  Any medically/clinically significant active infection.

          -  Symptoms of the SCLC spreading to the brain.

          -  Patients with limited stage SCLC who have undergone complete resection with no
             measurable disease prior to starting chemotherapy.

          -  Severe medical problems, unrelated to SCLC, that would limit the patient's full
             ability to follow all study rules and procedures, or that would expose the patient to
             extreme risk.

          -  Other ongoing, immunotherapy or radiotherapy being administered at the time as study
             participation.
Clinical trial NCT01153971 (phase 2, status: completed)
Conditions: non-hodgkin's lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: rituximab
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients 18-65 years of age;

          -  previously untreated indolent nonfollicular non-Hodgkin's lymphoma;

          -  active disease;

          -  >=3 involved sites.

        Exclusion Criteria:

          -  typical chronic lymphocytic leukemia;

          -  other malignancies within 3 years before study, except basal or squamous cell skin
             cancer or cancer in situ of the cervix;

          -  systemic corticosteroid use for >1 month;

          -  significant cardiovascular disease;

          -  central nervous system involvement;

          -  hepatitis B or C virus infection, or HIV infection.
Clinical trial NCT01437657 (phase 2, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: placebo, ro4917523 0.5 mg, ro4917523 1.5 mg
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC1=NC(C#CC2=CC=NC(Cl)=C2)=C(C)N1C1=CC=C(F)C=C1, CC1=NC(C#CC2=CC=NC(Cl)=C2)=C(C)N1C1=CC=C(F)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patient, 18 to 70 years of age at time of informed consent

          -  Major depressive disorder without psychotic features as defined by DSM-IV-TR criteria

          -  Inadequate response to ongoing antidepressant treatment, as defined by protocol

          -  Body mass index (BMI) 18 to 38 kg/m2 inclusive

        Exclusion Criteria:

          -  Currently receiving treatment with a combination of antidepressants (two or more), or
             an adjunctive potentiating treatment as defined by protocol

          -  Previously received RO4917523

          -  History of failure, or utilization during the current episode of Electroconvulsive
             Therapy (ECT) or repetitive Transcranial Magnetic Stimulation (rTMS)

          -  History of use at any time of Vagus Nerve Stimulation (VNS) or Deep Brain Stimulation
             (DBS)

          -  Current or past history of bipolar disorder (e.g. manic, hypomanic, or mixed episodes)

          -  Pregnant or lactating women
Clinical trial NCT00628810 (phase 2, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: fluorouracil, irinotecan hydrochloride, leucovorin calcium
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of metastatic adenocarcinoma of the colon or rectum

               -  Not curable by surgery

          -  Genotype UGT1A1*1/UGT1A1*1 or UGT1A1*1/ UGT1A1*28

          -  Measurable disease

          -  No original tumor in place

          -  No secondary cerebral metastases

        PATIENT CHARACTERISTICS:

        Inclusion criteria:

          -  WHO performance status 0-2

          -  Life expectancy ≥ 3 months

          -  Absolute neutrophil count ≥ 1,500/mm3

          -  Platelet count ≥ 100,000/mm3

          -  Hemoglobin ≥ 9.0 g/dL

          -  Total bilirubin ≤ 1.5 times normal

          -  Alkaline phosphatase ≤ 2.5 times normal (5 times normal if liver involvement)

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients of must use effective contraception

        Exclusion criteria:

          -  Progressive gastrointestinal ulcer, hemorrhagic ulcer, or perforation in the past 6
             months

          -  Enteropathy or chronic diarrhea

          -  Proteinuria > 500 mg/24 hours

          -  Active cardiac disease

          -  Uncontrolled hypertension

          -  Myocardial infarction in the past 12 months

          -  Angina

          -  NYHA grade II-IV congestive heart disease

          -  Severe arrhythmia even with treatment

          -  Peripheral vascular disease ≥ grade II

          -  Nonhealing wound, ulcer, or severe bone fracture

          -  Hemorrhagic diatheses or coagulopathy

          -  Severe or uncontrolled infection

          -  Severe or uncontrolled medical condition

          -  Other malignant disease in the past 5 years except curatively treated basal cell skin
             cancer or carcinoma in situ of the uterine cervix

          -  Severe traumatic injury within the past 4 weeks

        PRIOR CONCURRENT THERAPY:

          -  No prior chemotherapy for metastatic disease

               -  One prior regimen of chemotherapy in the neoadjuvant or adjuvant setting for the
                  original tumor allowed

          -  At least 6 months since prior chemotherapy

          -  No prior irinotecan hydrochloride or bevacizumab

          -  No oral or parenteral anticoagulant therapy within the past 10 days

               -  Warfarin allowed provided INR < 1.5

          -  No major surgery or biopsy within the past 4 weeks

          -  No puncture in the past 7 days

          -  No planned major surgery

          -  No concurrent daily or chronic aspirin (> 325 mg/day), anti-inflammatories, or
             steroids

          -  No other concurrent anticancer therapy
Clinical trial NCT01357837 (phase 2, status: completed)
Conditions: osteoarthritis of the knee
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: matching placebo, grt6005, grt6005, grt6005
SMILES: CC1=CC(O)=CC(C)=C1Cl, [H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O, [H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O, [H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O
Eligibility criteria:

        Inclusion Criteria:

          -  painful Osteoarthritis of the knee based on American College of Rheumatology Criteria

          -  signed informed consent

          -  on stable analgesic medications for painful osteoarthritis with regular analgesic
             intake for at least 3 months

          -  pain intensity score of 4 or greater on the 11-point numeric rating scale (where 0
             indicates "no pain" and 10 indicates "pain as bad as you can imagine").

        Exclusion Criteria:

          -  Substance Abuse

          -  Significant cardiac disease

          -  Presence of risk factors for Torsades de Pointes and chronic severe cardiac disease

          -  History of seizure disorder

          -  Chronic gastrointestinal disease

          -  Conditions that contribute and confound to the assessment of pain

          -  Surgery or painful procedure during or within 3 months of enrollment

          -  Cancer

          -  Subjects with impaired renal function

          -  Subjects with impaired hepatic function

          -  Female subjects who are breastfeeding

          -  History of chronic hepatitis B or C or human immunodeficiency virus infection, or
             presence of acute hepatitis A, B, or C within the past 3 months.

          -  Clinically relevant history of hypersensitivity or allergy to paracetamol, opioids or
             the excipients.
Clinical trial NCT01808248 (phase 2, status: completed)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: sof, peg, rbv
SMILES: CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Infection with genotype 2 or 3 HCV infection

          -  Cirrhosis determination

          -  Individual is treatment-experienced

          -  Screening laboratory values within defined thresholds

          -  Individual has not been treated with any investigational drug or device within 30 days
             of the Screening visit

          -  Use of highly effective contraception methods if female of childbearing potential or
             sexually active male

        Exclusion Criteria:

          -  Prior exposure to a direct-acting antiviral drug targeting the HCV NS5B polymerase

          -  Pregnant or nursing female or male with pregnant female partner

          -  Current or prior history of clinical hepatic decompensation

          -  History of clinically-significant illness or any other major medical disorder that may
             interfere with treatment, assessment, or compliance with the study protocol

          -  Excessive alcohol ingestion or significant drug abuse
Clinical trial NCT01125787 (phase 2, status: terminated)
Conditions: chronic lymphocytic leukemia (cll)
ICD codes: A87.2, K52.832, D72.111, C91.11, C91.12, C91.10
Drugs: ofatumumab + bendamustine
SMILES: CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl
Reason stopped: 
    low enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Must be >/= 18 years old and able to provide consent

          -  Must have diagnosis of CLL as defined by NCI criteria

          -  Must be previously untreated for CLL

          -  Must require chemotherapy

          -  serum creatinine <1.8 mg/dl

          -  Bilirubin must be </= 2 mg/d, unless secondary to tumor

          -  Must have adequate liver function (as defined as <2x ULN, unless related to CLL)

          -  Performance status 0-2

          -  Women of child bearing age must be willing to use accepted/effective method of birth
             control.

        Exclusion Criteria:

          -  Not have received prior treatment with cytotoxic chemotherapy or immunotherapy.

          -  Not have autoimmune hemolytic anemia or autoimmune thrombocytopenia

          -  Not have history of corticosteroid treatment for CLL

          -  Not have CNS disease

          -  Not have clinically significant infections

          -  Patients with a second malignancy, other than basal cell carcinoma of the skin or in
             situ carcinoma of the cervix are not eligible.

          -  Not have positive serology for Hepatitis B or Hepatitis C

          -  Not have be known to be HIV positive

          -  Not have New York Classification III or IV hear disease
Clinical trial NCT00690885 (phase 2, status: terminated)
Conditions: pulmonary disease, chronic obstructive, pulmonary fibrosis, cough
ICD codes: J44.9, J44.1, J44.0, J84.10, J84.112, E84.0, J84.178, R05.1, R05.2, R05.3, R05.4, R05.9, G44.83, J45.991
Drugs: interferon-alpha lozenges, placebo lozenges
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    insufficient patient accrual
  
Eligibility criteria:

        Inclusion Criteria:

        For all patients

          -  history of clinically significant chronic cough for > 3 months

          -  For COPD patients

          -  >40 years of age

          -  20-pack-year history of smoking

          -  GOLD classification of Stage 1 or higher

          -  For IPF patients

          -  > 50 years of age

          -  history of unexplained dyspnea on exertion of > 3 months

          -  exhibits coughing and bilateral, basilar, inspiratory crackles on physical exam

          -  presents as being in a stable phase of IPF

          -  lung biopsy or HRCT indicative of IPF

        Exclusion Criteria:

          -  ACE inhibitor use

          -  GERD

          -  current cancer or history of lung cancer

          -  non-ambulatory

          -  hospitalized in the previous 12 months for heart failure
Clinical trial NCT00294190 (phase 2, status: completed)
Conditions: small cell lung cancer, carcinoma, small cell
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: topotecan
SMILES: CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Extensive small cell lung cancer with progression after one previous chemotherapy or
             chemotherapy/radiation therapy regimen

          -  Measurable or evaluable disease

          -  Able to perform activities of daily living with minimal assistance

          -  Adequate bone marrow, liver and kidney function

          -  May have received no more than 3 previous courses of radiation therapy

          -  Give written informed consent prior to study entry

        Exclusion Criteria:

          -  Patients with limited stage disease

          -  History of a prior malignancy within three years

          -  Female patients who are pregnant or are breast feeding

          -  Significant history of uncontrolled cardiac disease

          -  Myocardial infarction or stroke within six months

          -  Symptomatic peripheral vascular disease

          -  CNS involvement

          -  Serious active infection or underlying medical condition
Clinical trial NCT01485770 (phase 2, status: completed)
Conditions: narcolepsy
ICD codes: G47.411, G47.419, G47.421, G47.429
Drugs: adx-n05, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of narcolepsy

          -  Good general health

          -  Willing and able to comply with the study design and schedule and other requirements

        Exclusion Criteria:

          -  If female, pregnant or lactating

          -  Customary bedtime later than midnight

          -  History of significant medical condition, behavioral or psychiatric disorder
             (including suicidal ideation), or surgical history

          -  Any other clinically relevant medical, behavioral or psychiatric disorder other than
             narcolepsy that is associated with excessive sleepiness

          -  History of significant cardiovascular disease

          -  Body mass index >34

          -  Excessive caffeine use - > 600 mg/day of caffeine or > 6 cups of coffee/day

          -  History of alcohol or drug abuse within the past two years

          -  Nicotine dependence that has an affect on sleep
Clinical trial NCT00233623 (phase 2, status: withdrawn)
Conditions: metastatic colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: iressa (gefitinib), irinotecan, 5fluorouracil, leucovorin
SMILES: COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O, FC1=CNC(=O)NC1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed metastatic colorectal cancer

          -  Presence of measurable metastases

          -  No previous treatment for metastatic cancer

        Exclusion Criteria:

          -  No presence of Central Nervous System metastases

          -  No other co-existing malignancies or malignancies diagnosed within the last 5 years
             with the exception of basal cell carcinoma or cervical cancer in situ

          -  Any evidence of severe or uncontrolled systemic disease (e.g. unstable or
             uncompensated respiratory, cardiac, hepatic or renal disease)